The pharmacoeconomic analysis of medicines affecting the bone structure and mineralization
Keywords:bisphosphonates, postmenopause, osteoporosis, strontium ranelate, cost – effectiveness, pharmacoeconomic analysis
Osteoporosis is the most common metabolic disease of bones and is characterized by decrease of bone strength, which leads to a high risk of fractures. The seriousness of this disease is in its prolonged asymptomatic course; moreover, the disease affects a significant part of the population, especially older age groups.
Aim. To conduct the pharmacoeconomic analysis of the use of bisphosphonates in patients with postmenopausal osteoporosis by the cost-effectiveness method.
Materials and methods. The cost-effectiveness ratio was calculated. The average retail prices of medicines for 2017 obtained according to the data of the PharmXplorer analytical system of “Morion” company were used to calculate the cost of osteoporosis pharmacotherapy.
Results. Analysis of the cost of treatment showed that Alendon-70 (Micro Labs) was the cheapest drug in the alendronic acid group; its cost per treatment course for three years was 1092 UAH. Ibandronic acid-Vista, 150 mg, (Mistral Capital Management) was the cheapest drug in the group of ibandronic acid; its cost per course of treatment for three years was 11,405.88 UAH. Medicines on the basis of strontium ranelate were presented at the Ukrainian market only by one manufacturer. The results of the pharmacoeconomic analysis showed that ibandronate was the dominant method compared to strontium ranelate since it was more effective (62.0 % versus 41.0 %) and had a lower value for the cost-effectiveness ratio (18,396.58 UAH versus 150,602.56 UAH).
Conclusions. The data obtained suggest that the use of bisphosphonates, including ibandronate, is effective and cost-effective in menopausal osteoporosis.
Vertkin A.L., Arutyunov S.D., Sharov M.N. i dr. Osteoporoz v obschemeditsinskoy praktike. - Metod rekom. - M. – 2008. – 46 s.
Pasieshvili L. M. Osteoporoz — bezmolvnyiy kostnyiy «vor» // ShidnoEvropeyskiy zhurnal vnutrishnoYi ta simeynoYi meditsini. – 2015. – №1. – S. 19-23.
Povoroznyuk V.V., Grigoreva N.V. Menopauza i osteoporoz // Ekspres. - Kiev. – 2002. - 356 s.
Povoroznjuk V.V., Dzerovich N.I., Karasevskaya T.A. (2007) Bone mineral density in Ukrainian women of different age. Ann. New York Academy Sciences, 1119: 243–252.
Nasonov E.L. Profilaktika i lechenie osteoporoza: sovremennoe sostoyanie problemyi. // Russkiy meditsinskiy zhurnal. – 1998. – № 6. – S. 1176–1180.
Shishkova V.N. Profilaktika i terapiya osteoporoza. - Meditsinskie vesti. - 2011. - № 7. – S. 548.
Alekseeva L. I. Alendronat v lechenii osteoporoza// Consilium medicum. – 2012. – T.14, № 2. – S. 71-75.
Belovol A.N., Knyazkova I.I. Bisfosfonatyi v lechenii osteoporoza Klinicheskaya farmakologiya i terapIya. - 2014. № 23 (5). – S. 75-79.
Rizzoli R. Atlas of postmenopausal osteoporosis. — Current Medicine Group, 2005. — P. 25–90.
Yakovleva, L. V. Farmakoepidemiologichni doslidzhennya spozhivannya antibiotikiv iz grupi karbapenemiv / l. V. Yakovleva, N. O. Matyashova // Klinichna farmatsiya. - 2013. - № 1. - s. 4-7. - Bibliogr. : s. 6
Golovach I.Yu., Kochish A.Yu. Problema atipichnyih perelomov bedra na fone priema bisfosfonatov: strategicheskie i takticheskie voprosyi lecheniya osteoporoza. // Ratsionalnaya farmakoterapIya. - 2013. - № 4 (29). – S. 29-36.
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).